Key Takeaways:
Moderna shares surged as much as 177% Wednesday after its personalized cancer vaccine met both primary endpoints in a Phase 3 melanoma trial.
"This is a watershed moment for Moderna," Alec Stranahan, analyst at Bank of America, said. The firm upgraded Moderna to Neutral from Underperform, raising its price target to $170 from $40.
The INTerpath-001 trial enrolled 1,137 patients with resected stage IIB-IV melanoma. Intismeran plus Keytruda reduced recurrence and distant spread versus Keytruda alone. Hazard ratios, confidence intervals and overall-survival data were not disclosed. The Phase 2b KEYNOTE-942 study showed a 49% lower recurrence or death risk at five years and a 59% lower distant metastasis risk.
The readout is the first positive late-stage result for an mRNA cancer vaccine, moving Moderna's oncology platform closer to regulatory filing. The premarket move implied an equity value near $39.5 billion, up about $14.4 billion from Tuesday's close. Merck shares rose 3.91% premarket to $140.46.
The $99.02 premarket indication outran every recent analyst target shown by Google Finance. The quote stood 28.6% above Piper Sandler's $77 high target and more than double the $48.92 average. Google Finance lists one Buy, 12 Hold and two Sell ratings among 15 analysts.
Stranahan said the readout allows Moderna to diversify away from infectious disease and potentially ease persistent capital overhangs. BofA's model now assumes $54 billion in unadjusted global peak sales for intismeran, with Moderna splitting economics evenly with Merck. Upside could come from expanding Keytruda's use into PD-L1 negative and earlier-stage lung cancer patients, though the analyst cautioned this remains data-dependent.
Moderna's balance sheet gives it room to prepare for a filing. The company held $6.9 billion in cash and investments at June 30, then paid $950 million in July for a litigation settlement. Management expects $4.7 billion to $5.2 billion at year-end. Q2 revenue was $145 million with a GAAP net loss of $782 million.
Shares fell over 10% in premarket trading Thursday, while Merck slipped more than 1%. The pullback came as investors digested the topline data, which lacks effect sizes and mature survival curves. Stranahan noted that a hazard ratio of 0.6 to 0.7 at an upcoming medical meeting, likely the European Society for Medical Oncology conference, would be needed to turn more positive.
The full Phase 3 curves will determine the next valuation reset. Until then, the market has priced in more than clinical success — it has priced in a faster oncology transition for Moderna. Investors will watch the ESMO presentation and regulatory discussions for the next major event.
This article is for informational purposes only and does not constitute investment advice.
